ClinicalTrials.Veeva

Menu

Efficacy, Tolerance and Satisfaction With CLOBEX® Spray When Used as Monotherapy or Add-on Therapy in Plaque Psoriasis

Galderma logo

Galderma

Status

Completed

Conditions

Psoriasis

Treatments

Drug: Clobetasol propionate, 0.05% Spray
Drug: Clobetasol Propionate, 0.05%

Study type

Observational

Funder types

Industry

Identifiers

NCT00437216
US10029

Details and patient eligibility

About

Evaluation of the effectiveness of Clobex® Spray, 0.05% when used as monotherapy or add-on therapy to existing systemic or topical anti-psoriatic agents.

Full description

Evaluation of the effectiveness of Clobex® Spray, 0.05% when used as monotherapy or add-on therapy to existing systemic or topical anti-psoriatic agents, as determined by the change in the target plaque severity (TPS) rating between Weeks 0 and 4.

Enrollment

2,488 patients

Sex

All

Ages

18 to 80 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Moderate to severe plaque psoriasis between 3% and 20% of Body Surface Area (BSA) with a target plaque severity (TPS) of moderate to severe
  • At least 1 target site (not on the palms or soles of the feet) with a TPS rating of moderate to severe and with 1 or more elevated, easily palpable, plaques having well-circumscribed margins, and at least 1 cm in diameter
  • History of stable plaque psoriasis of greater than or equal to 3 months

Exclusion criteria

  • Diagnosis of guttate, generalized pustular, erythrodermic, psoriatic arthritis, or nail psoriasis as the sole or predominant form of psoriasis
  • Psoriatic arthritis that was not stable or might have required a change in medication during the 4-week study period
  • Plaque psoriasis requiring treatment on the face, scalp, neck, groin, and armpits

Trial design

2,488 participants in 2 patient groups

1
Description:
Monotherapy - Subjects who are not currently being treated with anti-psoriatic medication and start using Clobex®
Treatment:
Drug: Clobetasol Propionate, 0.05%
2
Description:
Add-on therapy - Subjects who are taking some form of anti-psoriatic medication and add Clobex® treatment
Treatment:
Drug: Clobetasol propionate, 0.05% Spray

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems